Related Experiment Video
Updated: Jun 19, 2026

04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Therapies for neurologic erectile dysfunction
Garrett H Lischer1, Ajay Nehra
1Department of Urology, Mayo Clinic, 200 1stStreet SW, Rochester, MN 55905 USA.
Expert Review of Neurotherapeutics
|October 9, 2009
Summary
Neurologic conditions can cause erectile dysfunction (ED) in men. Understanding the nervous system
Area of Science:
- Neuroscience
- Urology
Background:
- Erectile dysfunction (ED) can stem from neurologic or neurodegenerative conditions.
- Normal erectile function relies on complex interactions between the central nervous system (CNS), peripheral nervous system, and penile corporal bodies.
Purpose of the Study:
- To explore the link between neurologic conditions and erectile dysfunction.
- To discuss the disruption of neural pathways in ED.
- To review current and future therapeutic strategies for neurogenic ED.
Main Methods:
- Literature review and synthesis of existing research on neurogenic erectile dysfunction.
- Discussion of the neuroanatomy and neurophysiology of erectile function.
- Analysis of current treatment modalities and future research directions.
Main Results:
- Specific neurologic conditions directly cause erectile dysfunction by disrupting neural signaling.
- The interplay between the CNS, peripheral nerves, and penile tissues is crucial for erections.
- Existing treatments include oral medications, injectables, and surgery.
Conclusions:
- Neurologic and neurodegenerative diseases are significant causes of erectile dysfunction in a subset of men.
- Targeting neural pathways offers therapeutic potential for ED.
- Future research aims to enhance current treatments and develop novel long-term solutions for neurogenic ED.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Male Sexual Response: Erection & Ejaculation
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...